Yahoo
NasdaqCM - Delayed Quote USD

Adial Pharmaceuticals, Inc. (ADIL)

7.12 +0.46 (+6.91%)
At close: September 4 at 4:00:01 PM EDT
7.22 +0.10 (+1.40%)
After hours: September 4 at 7:42:15 PM EDT
Chart Range Bar
Loading chart for ADIL
  • Previous Close 6.66
  • Open 6.61
  • Bid 4.57 x 100
  • Ask 3.08 x 100
  • Day's Range 6.27 - 7.20
  • 52 Week Range 1.31 - 10.75
  • Volume 48,386
  • Avg. Volume 414,711
  • Market Cap (intraday) 20.888M
  • Beta (5Y Monthly) 1.39
  • PE Ratio (TTM) --
  • EPS (TTM) -17.71
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.33

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

www.adial.com

5

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ADIL
29.45%
S&P 500 (^GSPC)
12.75%

1-Year Return

ADIL
18.63%
S&P 500 (^GSPC)
18.71%

3-Year Return

ADIL
93.24%
S&P 500 (^GSPC)
70.93%

5-Year Return

ADIL
99.74%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -51.99M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-50M
-40M
-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

6.00 Low
8.33 Average
7.12 Current
11.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/3/2026
Analyst Alliance Global Partners
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 11

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -40.02%

  • Return on Equity (ttm)

    -2,011.64%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -57.8M

  • Diluted EPS (ttm)

    -17.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.71M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.93M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: